The Goldman Sachs Group Has Lowered Expectations for Seres Therapeutics (NASDAQ:MCRB) Stock Price

Seres Therapeutics (NASDAQ:MCRB) had its price target decreased by The Goldman Sachs Group from $1.00 to $0.75 in a research note published on Friday,Benzinga reports. The Goldman Sachs Group currently has a sell rating on the biotechnology company’s stock.

Several other research analysts also recently commented on MCRB. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Stock Performance

Seres Therapeutics stock opened at $0.69 on Friday. The stock has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.83. The stock has a market capitalization of $120.10 million, a P/E ratio of -3.00 and a beta of 2.19. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vontobel Holding Ltd. boosted its stake in Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 543,469 shares during the period. Geode Capital Management LLC increased its stake in shares of Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 222,771 shares in the last quarter. FMR LLC boosted its position in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.